{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:05:46Z","timestamp":1771232746539,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T00:00:00Z","timestamp":1469836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10557-016-6678-x","type":"journal-article","created":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T02:17:00Z","timestamp":1469845020000},"page":"407-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Ivabradine in the Management of Angina Pectoris"],"prefix":"10.1007","volume":"30","author":[{"given":"Alessandra","family":"Giavarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranil","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,30]]},"reference":[{"key":"6678_CR1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrcardio.2009.47","volume":"6","author":"R Silva De","year":"2009","unstructured":"De Silva R, Fox KM. Ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol. 2009;6:329\u201330.","journal-title":"Nat Rev Cardiol"},{"key":"6678_CR2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2010.143","volume":"7","author":"R Silva De","year":"2010","unstructured":"De Silva R, Fox KM. Pharmacotherapy: xanthine oxidase inhibition for relief of angina pectoris. Nat Rev Cardiol. 2010;7:603\u20134.","journal-title":"Nat Rev Cardiol"},{"key":"6678_CR3","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht310.P4876","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J"},{"key":"6678_CR4","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354\u2013471.","journal-title":"Circulation"},{"key":"6678_CR5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/heartjnl-2011-301436","volume":"98","author":"RA Henderson","year":"2012","unstructured":"Henderson RA, O\u2019Flynn N, Group GD. Management of stable angina: summary of NICE guidance. Heart. 2012;98:500\u20137.","journal-title":"Heart"},{"key":"6678_CR6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/FJC.0b013e31823e5e01","volume":"59","author":"Y Fang","year":"2012","unstructured":"Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F, et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol. 2012;59:260\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6678_CR7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","volume":"50","author":"K Fox","year":"2007","unstructured":"Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"6678_CR8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1081\/CEH-200031959","volume":"26","author":"P1 Palatini","year":"2004","unstructured":"Palatini P1, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. In Exp Hypertens. 2004;26:637\u201344.","journal-title":"In Exp Hypertens"},{"key":"6678_CR9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/pgmj.2009.084384","volume":"86","author":"CA Daly","year":"2010","unstructured":"Daly CA, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, et al. Euro Heart Survey Investigators. Inadequate control of heart rate in patients with stable angina: results from the European Heart Survey. Postgrad Med J. 2010;86:212\u20137.","journal-title":"Postgrad Med J"},{"issue":"3","key":"6678_CR10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jacc.2014.04.042","volume":"64","author":"C Andersson","year":"2014","unstructured":"Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd DB, Hlatky MA. \u03b2-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64(3):247\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"6678_CR11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","volume":"106","author":"D Francesco Di","year":"2010","unstructured":"Di Francesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106:434\u201346.","journal-title":"Circ Res"},{"key":"6678_CR12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1540-8167.2006.00736.x","volume":"18","author":"A Barbuti","year":"2007","unstructured":"Barbuti A, Baruscotti M, DiFrancesco D. The pacemaker current: from basics to the clinics. J Cardiovasc Electrophysiol. 2007;18:342\u20137.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"6678_CR13","doi-asserted-by":"crossref","unstructured":"Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014:1001506\u201310.","DOI":"10.1136\/heartjnl-2014-305482"},{"key":"6678_CR14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrd3576","volume":"10","author":"O Postea","year":"2011","unstructured":"Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov. 2011;10:903\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"6678_CR15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s12325-015-0237-x","volume":"32","author":"E Tagliamonte","year":"2015","unstructured":"Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C, Capuano N. Ivabradine and bisoprolol on Doppler-derived coronary flow velocity Reserve in Patients with stable coronary artery disease: beyond the heart rate. Adv Ther. 2015;32:757\u201367.","journal-title":"Adv Ther"},{"key":"6678_CR16","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","volume":"64","author":"D Francesco Di","year":"2004","unstructured":"Di Francesco D, John AC. Heart rate lowering by specific and selective I f current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757\u201365.","journal-title":"Drugs"},{"key":"6678_CR17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2010.10.065","volume":"107","author":"M Tendera","year":"2011","unstructured":"Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R. Ford I et al; BEAUTIFUL investigators. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol. 2011;107:805\u201311.","journal-title":"Am J Cardiol"},{"key":"6678_CR18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/eurheartj\/ehr255","volume":"33","author":"SH Schirmer","year":"2012","unstructured":"Schirmer SH, Degen A, Baumh\u00e4kel M, et al. Heart-rate reduction by I f -channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J. 2012;33:1223\u201331.","journal-title":"Eur Heart J"},{"key":"6678_CR19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/heartjnl-2013-304880","volume":"100","author":"S Gloekler","year":"2014","unstructured":"Gloekler S, Traupe T, Stoller M, Schild D, Steck H, Khattab A, et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014;100:160\u20136.","journal-title":"Heart"},{"key":"6678_CR20","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1161\/CIRCULATIONAHA.107.746537","volume":"117","author":"F Custodis","year":"2008","unstructured":"Custodis F, Baumh\u00e4kel M, Schlimmer N, List F, Gensch C, B\u00f6hm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and preventsatherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117:2377\u201387.","journal-title":"Circulation"},{"key":"6678_CR21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s12325-015-0253-x","volume":"32","author":"L Jedlickova","year":"2015","unstructured":"Jedlickova L, Merkovska L, Jackova L, Janicko M, Fedacko J, Novakova B, et al. Effect of ivabradine on endothelial function in patients with stable angina pectoris: assessment with the Endo-PAT 2000 device. Adv Ther. 2015;32:962\u201370.","journal-title":"Adv Ther"},{"key":"6678_CR22","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehn337","volume":"29","author":"G Heusch","year":"2008","unstructured":"Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008;29:2265\u201375.","journal-title":"Eur Heart J"},{"key":"6678_CR23","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1111\/bph.13220","volume":"172","author":"P Kleinbongard","year":"2015","unstructured":"Kleinbongard P, Gedik N, Witting P, Freedman B, Kl\u00f6cker N, Heusch G. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol. 2015;172:4380\u201390.","journal-title":"Br J Pharmacol"},{"key":"6678_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00395-015-0511-8","volume":"110","author":"F Maranta","year":"2015","unstructured":"Maranta F, Tondi L, Agricola E, Margonato A, Rimoldi O, Camici PG. Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia. Basic Res Cardiol. 2015;110:55.","journal-title":"Basic Res Cardiol"},{"key":"6678_CR25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ehj.2003.10.010","volume":"25","author":"X Monnet","year":"2004","unstructured":"Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004;25:579\u201386.","journal-title":"Eur Heart J"},{"key":"6678_CR26","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1161\/01.CIR.96.9.3205","volume":"96","author":"PG Camici","year":"1997","unstructured":"Camici PG, Wijns W, Borgers M, De Silva R, Ferrari R, Knuuti J, et al. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation. 1997;96:3205\u201314.","journal-title":"Circulation"},{"key":"6678_CR27","unstructured":"Procoralan Summary of Product Characteristics [online]. 2012 http:\/\/www.medicines.org.uk\/EMC\/medicine\/17188\/SPC\/Procoralan\/ . Accessed 26 Jul 2012."},{"key":"6678_CR28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00002018-200831020-00001","volume":"31","author":"I Savelieva","year":"2008","unstructured":"Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31:95\u2013107.","journal-title":"Drug Saf"},{"key":"6678_CR29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G, Group II. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817\u201323.","journal-title":"Circulation"},{"key":"6678_CR30","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529\u201336.","journal-title":"Eur Heart J"},{"key":"6678_CR31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","volume":"67","author":"W Ruzyllo","year":"2007","unstructured":"Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393\u2013405.","journal-title":"Drugs"},{"key":"6678_CR32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/hrt.48.4.309","volume":"48","author":"KM Fox","year":"1982","unstructured":"Fox KM. Exercise heart rate\/ST segment relation. Perfect predictor of coronary disease. Br Heart J. 1982;48:309\u201310.","journal-title":"Br Heart J"},{"key":"6678_CR33","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","volume":"27","author":"GH Gislason","year":"2006","unstructured":"Gislason GH, Rasmussen JN, Abildstr\u00f8m SZ, Gadsb\u00f8ll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153\u20138.","journal-title":"Eur Heart J"},{"key":"6678_CR34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","volume":"27","author":"K Fox","year":"2006","unstructured":"Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341\u201381.","journal-title":"Eur Heart J"},{"key":"6678_CR35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0735-1097(02)02848-6","volume":"41","author":"RJ Gibbons","year":"2003","unstructured":"Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC\/AHA 2002 guideline update for the management of patients with chronic stable angina\u2014summary article: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines (committee on the Management of Patients with Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159\u201368.","journal-title":"J Am Coll Cardiol"},{"key":"6678_CR36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.eurheartj.a014699","volume":"17","author":"KM Fox","year":"1996","unstructured":"Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total ischaemic burden European trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET study group. Eur Heart J. 1996;17:96\u2013103.","journal-title":"Eur Heart J"},{"key":"6678_CR37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00019501-200212000-00008","volume":"13","author":"WW Klein","year":"2002","unstructured":"Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis. 2002;13:427\u201336.","journal-title":"Coron Artery Dis"},{"key":"6678_CR38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0002-9149(97)00893-X","volume":"81","author":"CJ Knight","year":"1998","unstructured":"Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European studies in angina research (CESAR) investigators. Am J Cardiol. 1998;81:133\u20136.","journal-title":"Am J Cardiol"},{"key":"6678_CR39","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa043012","volume":"52","author":"X Jouven","year":"2005","unstructured":"Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon M, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;52:1951\u20138.","journal-title":"N Engl J Med"},{"key":"6678_CR40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","volume":"26","author":"A Diaz","year":"2005","unstructured":"Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967\u201374.","journal-title":"Eur Heart J"},{"issue":"Suppl H","key":"6678_CR41","first-page":"64","volume":"1","author":"JK Kjekshus","year":"1999","unstructured":"Kjekshus JK, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999;1(Suppl H):64\u20139.","journal-title":"Eur Heart J"},{"key":"6678_CR42","doi-asserted-by":"crossref","first-page":"43F","DOI":"10.1016\/0002-9149(86)90888-X","volume":"57","author":"JK Kjekshus","year":"1986","unstructured":"Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986;57:43F\u20139F.","journal-title":"Am J Cardiol"},{"key":"6678_CR43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.1999.00924.x","volume":"47","author":"JA Vring van der","year":"1999","unstructured":"van der Vring JA, Daniels MC, Holwerda NJ, et al. Combination of calcium channel blockers and \u03b2-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Br J Clin Pharmacol. 1999;47:493\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"6678_CR44","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"JC Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T, Study Investigators ASSOCIATE. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540\u20138.","journal-title":"Eur Heart J"},{"key":"6678_CR45","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ijcard.2012.10.011","volume":"168","author":"JC Tardif","year":"2013","unstructured":"Tardif JC, Ponikowski P, Kahan T, Investigators ASSOCIATE. Effects of ivabradine in patients with stable angina receiving \u03b2-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2013;168:789\u201394.","journal-title":"Int J Cardiol"},{"key":"6678_CR46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators BEAUTIFUL. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807\u201316.","journal-title":"Lancet"},{"key":"6678_CR47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2007.08.077","volume":"126","author":"GD Giannoglou","year":"2008","unstructured":"Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008;126:302\u201312.","journal-title":"Int J Cardiol"},{"key":"6678_CR48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/hc3801.096325","volume":"104","author":"UE Heidland","year":"2001","unstructured":"Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477\u201382.","journal-title":"Circulation"},{"key":"6678_CR49","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford SPG, Tendera M, Robertson M, Ferrari R. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817\u201321.","journal-title":"Lancet"},{"key":"6678_CR50","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","volume":"30","author":"K Fox","year":"2009","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, Investigators BEAUTIFUL. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337\u201345.","journal-title":"Eur Heart J"},{"key":"6678_CR51","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, Investigators SIGNIFY. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091\u20139.","journal-title":"N Engl J Med"},{"key":"6678_CR52","doi-asserted-by":"crossref","unstructured":"Tendera M, Chassany O, Ferrari R, Ford I, Steg PG, Tardif JC, Fox K. Quality of life with ivabradine in patients with angina pectoris: the study assessing the morbidity-mortality benefits of the if inhibitor ivabradine in patients with coronary artery disease quality of life Substudy. Circ Cardiovasc Qual Outcomes. 2016;9:31\u20138.","DOI":"10.1161\/CIRCOUTCOMES.115.002091"},{"key":"6678_CR53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","volume":"101","author":"K Werdan","year":"2012","unstructured":"Werdan K, Ebelt H, Nuding S, H\u00f6pfner F, Hack G, M\u00fcller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONSstudy. Clin Res Cardiol. 2012;101:365\u201373.","journal-title":"Clin Res Cardiol"},{"key":"6678_CR54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2009.08.642","volume":"105","author":"JS Borer","year":"2010","unstructured":"Borer JS, Tardif JC. Efficacy of ivabradine, a selective If inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol. 2010;105:29\u201335.","journal-title":"Am J Cardiol"},{"key":"6678_CR55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.exger.2014.09.002","volume":"59","author":"U M\u00fcller-Werdan","year":"2014","unstructured":"M\u00fcller-Werdan U, St\u00f6ckl G, Ebelt H, Nuding S, H\u00f6pfner F, Werdan K, Study Investigators ADDITIONS. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014;59:34\u201341.","journal-title":"Exp Gerontol"},{"key":"6678_CR56","doi-asserted-by":"crossref","unstructured":"Andell P, Erlinge D, Smith JG, Sundstr\u00f6m J, Lindahl B, James S, Koul S \u03b2-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study J Am Heart Assoc 2015;4: e001611.","DOI":"10.1161\/JAHA.114.001611"},{"key":"6678_CR57","first-page":"118","volume":"53","author":"G Andrikopoulos","year":"2012","unstructured":"Andrikopoulos G, Pastromas S, Kartalis A, Toli K, Mantas I, Tzeis S, et al. Inadequate heart rate control is associated with worse quality of life in patients with coronary artery disease and chronic obstructive pulmonary disease. The RYTHMOS study Hellenic J Cardiol. 2012;53:118\u201326.","journal-title":"The RYTHMOS study Hellenic J Cardiol"},{"key":"6678_CR58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","volume":"112","author":"A Villano","year":"2013","unstructured":"Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013;112:8\u201313.","journal-title":"Am J Cardiol"},{"key":"6678_CR59","unstructured":"European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor\/Procoralan (ivabradine). 2014, EMA\/705247\/2014 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2014\/11\/WC500177591.pdf"},{"key":"6678_CR60","doi-asserted-by":"crossref","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY investigators. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J 2015;36:3291\u20133296.","DOI":"10.1093\/eurheartj\/ehv451"},{"key":"6678_CR61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","volume":"15","author":"G Cocco","year":"2015","unstructured":"Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. Cardiovasc Toxicol. 2015;15:104\u20136.","journal-title":"Cardiovasc Toxicol"},{"key":"6678_CR62","first-page":"426","volume":"62","author":"SR Mittal","year":"2014","unstructured":"Mittal SR. Slow junctional rhythm, QTc prolongation and transient torsades depointes following combined use of ivabradine, diltiazem and ranolazine. J Assoc Physicians India. 2014;62:426\u20137.","journal-title":"J Assoc Physicians India"},{"key":"6678_CR63","doi-asserted-by":"crossref","unstructured":"Melgari D, Brack KE, Zhang C, Zhang Y, El Harchi A, Mitcheson JS, et al. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine. J Am Heart Assoc. 2015;4(4):e001813.","DOI":"10.1161\/JAHA.115.001813"},{"key":"6678_CR64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jacc.2014.04.043","volume":"64","author":"PG Steg","year":"2014","unstructured":"Steg PG, De Silva R. Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence? J Am Coll Cardiol. 2014;64:253\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"6678_CR65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s40265-013-0117-0","volume":"73","author":"P Deedwania","year":"2013","unstructured":"Deedwania P. Selective and specific inhibition of I f with ivabradine for the treatment of coronary artery disease or heart failure. Drugs. 2013;73:1569\u201386.","journal-title":"Drugs"},{"key":"6678_CR66","first-page":"3297","volume":"36","author":"JF Beltrame","year":"2015","unstructured":"Beltrame JF. Ivabradine and the SIGNIFY conundrum. Eur Heart J. 2015;36:3297\u20139.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-016-6678-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T19:49:20Z","timestamp":1568231360000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-016-6678-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,30]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["6678"],"URL":"https:\/\/doi.org\/10.1007\/s10557-016-6678-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,30]]}}}